Dermsquared Scheduled Maintenance, Thursday Feb 29, 6:30am to 8:30am EST

2023 Fall Clinical Virtual Grand Rounds

2023 Virtual Grand Rounds Session 11: September 13, 2023 - The Role of the IL17 Inhibitors in Targeted Management of Inflammatory Dermatologic Disorders

About

Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases and tools, delivered by the top experts in dermatology. Please join us for this week's session:

Wednesday, September 13, 2023

8 PM ET / 5 PM PT

The Role of the IL-17 Inhibitors Targeted in Management of Inflammatory Dermatologic Disorders

 

This activity is supported by an educational grant from UCB.

Availability

In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

September 14, 2023

Expiration Date:

September 14, 2024

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Explain the role of the IL-17 pathway in the pathophysiology of chronic inflammatory dermatologic disorders

  • Review data for IL-17 inhibitors for the management of inflammatory dermatologic disorders

  • Discuss strategies to educate patients about IL-17 inhibitors and incorporate these agents into clinical care

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Gary
Gary Goldenberg, MD

Assistant Clinical Professor of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Joseph
Joseph Merola, MD, MMSc

Professor and Chair
University of Texas Southwestern Medical Center
Dallas, TX 

Jennifer
Jennifer Soung, MD

Director of Clinical Research
Southern California Dermatology
Clinical Faculty
Harbor University of California Los Angeles
Santa Ana, CA

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Gary Goldenberg, MD

Grant/Research Support: Biofrontera 
Consultant: CoolHealth, Cutera, Galderma, Regeneron, Sanofi, Scibase 
Speakers’ Bureau or Honoraria: Regeneron Sanofi 
Ownership Interest: Verrica

Joseph F. Merola, MD, MMSc

Grant/Research Support: J. F. Merola is a consultant and/or investigator for Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Abbvie, Dermavant, Eli Lilly, Incyte, Moonlake, Novartis, Janssen, UCB, Sanofi-Regeneron Consultant: J. F. Merola is a consultant and/or investigator for Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Abbvie, Dermavant, Eli Lilly, Incyte, Moonlake, Novartis, Janssen, UCB, Sanofi-Regeneron

Jennifer Soung, MD

Advisory Board/Consultant: Arcutis Biotechnology; Bristol Myers Squibb Company; Dermavant Sciences, Inc. Novartis, Abbvie, Lily, Pfizer, LEO Pharma, Regeneron, Sanofi, Amgen, Dermavant, Janssen, UCB

Shareholder: Pfizer

Grant/Research Support: AbbVie Inc.; Amgen Inc.; Arcutis Biotechnology; Castle Biosciences; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; KoBio Labs; Kyowa Kirin; LEO Pharma, Inc.; Lilly; Novartis; Pfizer Inc.; UCB Pharma, Inc

Speaker's Bureau: AbbVie Inc.; Amgen Inc.; Arcutis Biotechnology; Bristol Myers Squibb Company; LEO Pharma, Inc.; Lilly; Novartis; Ortho Dermatologics; Pfizer Inc.; Regeneron, Sanofi, Dermavant, Janssen

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The Institute discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved